Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene Expression analysis of therapeutical response in Triple Negative Breast tumors.

ABSTRACT: 10 biopsies before treatment from triple negative patients with complete response were collected. Total RNA was extracted from tumor specimens and the whole transcriptome was quantified with Affymetrix HuGene1.1ST. The biopsies were classified into Good (major or complete) or Poor (absent or minor) therapeutic response subgroup.

ORGANISM(S): Homo sapiens

PROVIDER: GSE45898 | GEO | 2016/03/24

SECONDARY ACCESSION(S): PRJNA196618

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Gene Expression analysis of therapeutical response in Triple Negative Breast tumors.

Project description:10 biopsies before treatment from triple negative patients with complete response were collected. Total RNA was extracted from tumor specimens and the whole transcriptome was quantified with Affymetrix HuGene1.1ST. The biopsies were classified into Good (major or complete) or Poor (absent or minor) therapeutic response subgroup. Whole genome expression of triple negative breast cancer tissues were measured before neoadjuvant chemotherapy

2016-03-24 | E-GEOD-45898 | biostudies-arrayexpress

GeoMx digital spatial profiling on biopsies of triple negative breast cancer patients

Project description:In this study, we analyzed the differential spatial transcriptome of Triple-Negative Breast Cancer (TNBC) patients who responded in an opposite manner to neoadjuvant chemotherapy (NACT): we compared responders displaying pathological complete response (pCR) with no-responders who showed disease progression during therapy. Diagnostic TruCut biopsies were analyzed using the GeoMx Cancer Transcriptome Atlas (Nanostring).

2023-10-12 | E-MTAB-13069 | biostudies-arrayexpress

Transcription profiling of A. thaliana Col-0 wild type vs. myb11, myb12, myb111 triple mutant to identify targets of PFG

Project description:Comparison of Col-0 wt vs. Col myb11 myb12 myb111 triple mutant, screening for genes downregulated in the triple mutant; Screening for target genes of R2R3-MYB subgroup 7 transcription factors

2007-11-21 | E-ATMX-5 | biostudies-arrayexpress

RNAseq of triple negative breast cancer samples

Project description:We report RNAseq data from tumors obtained from patients with triple negative breast cancer Eight patients with II-III stageTNBC diagnosis (only one patient with IV oligometastatic stage) were included in the study. All patients received neoadjuvant chemotherapy based on sequential anthracyclines and taxanes ± platinum salts plus radiation therapy. Seven patients were evaluable for response and pathological complete response (RCB=0) was reached in 71.4% of the patients (2 patients with RCB=2). No patients received adjuvant systemic therapy.Tumor biopsies were obtained for RNAseq studies.

2022-10-20 | GSE206998 | GEO

Deep Sequencing Identifies IDH1 R132S Mutation in Adult Medulloblastoma (CGH)

2013-01-01 | GSE41990 | GEO

RNAseq study of synovial biopsies after triple DMARD treatment

Project description:Total RNA sequencing was performed on samples isolated from joint synovial biopsies from subjects with rheumatoid arthritis before and after 6 months of triple DMARD treatment

2017-09-20 | GSE97165 | GEO

Response to Neoadjuvant Chemotherapy in Triple Negative Breast tumors.

Project description:In a cohort study of 7 women with primary invasive breast cancer, we obtained a tumor specimen before (biopsy) and after (tumorectomy) 4 cycles of NAC with epirubicine and cyclophosphamide, followed by 4 cycles of taxanes. Total RNA was extracted from tumor specimens and the whole transcriptome was quantified with Affymetrix HuGene1.1ST. Molecular functions changing during chemotherapy were searched. Whole genome expression of triple negative breast cancer tissues were measured before and after four cycles neoadjuvant chemotherapy

2016-03-24 | E-GEOD-43816 | biostudies-arrayexpress

Deep Sequencing Identifies IDH1 R132S Mutation in Adult Medulloblastoma (CGH)

Project description:Here we present the case of adult medulloblastoma with minimal chromosomal rearrangements. Data presented here are aCGH analyses of two biopsies of adult patient with a medulloblastoma which was classified as a Shh subgroup. Analyses were performed on 2 archival specimens of medulloblastoma, WHO Grade IV, seen at the Department of Pathology, Massachusetts General Hospital from 2007. This Series represents the CGH part of the study.

2013-01-01 | E-GEOD-41990 | biostudies-arrayexpress

Identification of LncRNA Expression Signatures for Triple-negative Breast Cancer

Project description:To identify biologically and clinically novel lncRNAs potentially involved in the progression of breast cancer, we profiled the expression of lncRNAs in two stage III triple-negativebreast cancer tissues and their paired adjacent noncancerous tissues by LncRNA Array 3.0 (ArrayStar). Expression of the mostly upregulated lncRNA (BCAR4) from this signature was quantified in the breast caner tissue microarray by RNA In situ Hybridization and bioinformatic analysis of Oncomine database, confirming its correlation with breast cancer metastasis.

2014-12-01 | GSE60689 | GEO

(Phospho)proteomics profiling of pre-treatment HER2+ BC biopsies

Project description:In this study, we perform (phospho)proteomics analysis of 45 pre-treatment HER2+ needle biopsies of early-stage invasive breast cancer to identify molecular signatures predictive of treatment response to Trastuzumab, Pertuzumab and chemotherapy. All patient biopsies included in this study were classified as HER2+ with a minimum tumour grade of two and tumour cell density of 60% or higher. After needle biopsies were taken, patients completed multiple drug treatment cycles according to the regime of the TRAIN2 study. Finally, treatment response was determined at surgery. The systemic treatment response was categorised as pathological complete response (pCR = ypT0/isypN0) (n=26), near pCR (npCR) (n=8), or No pCR (n=11).

2023-09-20 | PXD034643 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data